Correlations between the long noncoding RNA MEG3 and clinical characteristics for diabetic kidney disease in type 2

Ke-Hsin Ting1,2,3,4, Po-Jen Yang5,6, Po-Yu Tsai4,7

  • 1Division of Cardiology, Department of Internal Medicine, Yunlin Branch, Changhua Christian Hospital, Yunlin, Taiwan.

PubMed
Abstract

Insights

The MEG3 SNP rs3087918 is less common in patients with diabetic kidney disease (DKD). This single-nucleotide polymorphism (SNP) is also linked to lower glycated hemoglobin (HbA1c) levels in type 2 diabetes mellitus (T2DM) patients.

Area of Science:

  • Genetics and Molecular Biology
  • Nephrology
  • Endocrinology

Background:

  • Diabetic kidney disease (DKD) is a significant complication of type 2 diabetes mellitus (T2DM), contributing to systemic inflammation.
  • Maternally expressed gene 3 (MEG3), a tumor suppressor, plays a role in regulating inflammation.

Purpose of the Study:

  • To investigate the association between DKD and the prevalence of single-nucleotide polymorphisms (SNPs) in the MEG3 gene.
  • To explore the relationship between MEG3 SNPs and glycemic control (HbA1c) in T2DM patients.

Main Methods:

  • Genotyping of five MEG3 SNPs (rs4081134, rs10144253, rs7158663, rs3087918, rs11160608) in 706 DKD patients and 735 non-DKD controls using TaqMan allelic discrimination.
  • Statistical analysis to determine the prevalence of genotypes in DKD and non-DKD groups, and their association with clinical parameters.

Main Results:

  • The GG genotype of MEG3 SNP rs3087918 was significantly less prevalent in the DKD group compared to the wild-type genotype.
  • In subgroups of pre-ESRD DKD patients and male DKD patients, the GG genotype of rs3087918 was also significantly less prevalent.
  • Higher glycated hemoglobin (HbA1c) levels were observed in T2DM patients, particularly males, with the wild-type genotype of MEG3 SNP rs3087918.

Conclusions:

  • MEG3 SNP rs3087918 is significantly less prevalent in individuals with diabetic kidney disease.
  • The presence of MEG3 SNP rs3087918 is associated with improved glycemic control, indicated by lower HbA1c levels in T2DM patients.